These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12199351)

  • 1. Use of bisphosphonates in children and adolescents.
    Allgrove J
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():921-8. PubMed ID: 12199351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate therapy for fibrous dysplasia.
    DiMeglio LA
    Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative indications for bisphosphonate therapy.
    Landesberg R; Eisig S; Fennoy I; Siris E
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):27-34. PubMed ID: 19371812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrous dysplasia of bone and McCune-Albright syndrome.
    Chapurlat RD; Orcel P
    Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):55-69. PubMed ID: 18328981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramedullary rodding and bisphosphonate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome.
    O'Sullivan M; Zacharin M
    J Pediatr Orthop; 2002; 22(2):255-60. PubMed ID: 11856942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The pharmacology of biphosphonates and their use in hypercalcemia].
    Adam Z; Vorlícek J; Tomíska M
    Vnitr Lek; 1994 Oct; 40(10):667-70. PubMed ID: 7810087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
    Toussaint ND; Elder GJ; Kerr PG
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
    Lala R; Matarazzo P; Andreo M; Marzari D; Bellone J; Corrias A; de Sanctis C;
    J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():583-93. PubMed ID: 16789621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate for fibrous dysplasia due to McCune Albright Syndrome.
    Kochar IP; Kulkarni KP
    Indian Pediatr; 2010 Jul; 47(7):633-5. PubMed ID: 20683120
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of stem cells in fibrous dysplasia of bone and the Mccune-Albright syndrome.
    Robey PG; Kuznetsov S; Riminucci M; Bianco P
    Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():386-94. PubMed ID: 17982385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [McCune-Albright syndrome: a difficult and complicated case study].
    Liang LY; Meng Z; Zeng QH; Li WY
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug; 8(4):311-4. PubMed ID: 16923365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
    Chan B; Zacharin M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2017-20. PubMed ID: 16551739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bisphosphonates in polyostotic fibrous dysplasia.
    Khadilkar VV; Khadilkar AV; Maskati GB
    Indian Pediatr; 2003 Sep; 40(9):894-6. PubMed ID: 14530553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
    Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
    Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.